You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

locally advanced esophageal squamous cell carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC Trial in Hanzhou (Cadonilimab Combined Albumin-paclitaxel,

Recruiting
  • The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
  • Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
  • Hanzhou, Zhejiang, China
    Lulu Liu
Jul 14, 2023

Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • AK104, nab-paclitaxel, carboplatin
  • Anyang, Henan, China
  • +1 more
Jun 1, 2023

Esophageal Carcinoma Trial (Immune Checkpoint Inhibitors)

Not yet recruiting
  • Esophageal Carcinoma
  • Immune Checkpoint Inhibitors
  • (no location specified)
Jul 6, 2023

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 30, 2023

Locally Advanced Esophageal Squamous Cell Carcinoma Trial (Tiragolumab)

Not yet recruiting
  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • (no location specified)
Feb 23, 2023

Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Sintilimab)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Aug 8, 2022

Esophageal Carcinoma Trial in Tianjin (camrelizumab)

Recruiting
  • Esophageal Carcinoma
  • Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Jul 25, 2022

Esophageal Squamous Cell Carcinoma Trial (AK104)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Oct 25, 2022

Esophagus Cancer Trial in Guangzhou (Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy)

Not yet recruiting
  • Esophagus Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Nov 20, 2023

Esophagus Cancer Trial in Xiamen (Tislelizumab, Paclitaxel-albumin, Carboplatin)

Recruiting
  • Esophagus Cancer
  • Xiamen, Fujian, China
    ShanghaiZhongshan
Apr 8, 2023

Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Trial (Esophageal arterial infusion chemo, Systemic intravenous

Not yet recruiting
  • Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
  • Esophageal arterial infusion chemotherapy
  • Systemic intravenous chemotherapy
  • (no location specified)
May 15, 2022

Esophageal Squamous Cell Carcinoma Trial in Taipei City (Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Taipei City, Taiwan
    National Taiwan University Hospital
Jun 5, 2022

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Dec 6, 2022

Esophageal Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab, Carboplatin or Cisplatin, Docetaxel)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Mar 30, 2022

Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer Trial in Guangzhou (drug, radiation, procedure)

Recruiting
  • Squamous Cell Esophageal Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 11, 2022

Esophageal Squamous Cell Carcinoma Trial in Chengdu (Toripalimab)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Feb 8, 2022

Esophageal Squamous Cell Carcinoma Trial (QL1706)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Aug 4, 2022

Locally Advanced Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (SHR-1210+docetaxel+nedaplatin, SHR-1210+Apatinib)

Recruiting
  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 16, 2022

Surgical Procedure, Unspecified Trial in Shanghai (ROBOTIC-ASSISTED ESOPHAGECTOMY)

Not yet recruiting
  • Surgical Procedure, Unspecified
  • ROBOTIC-ASSISTED ESOPHAGECTOMY
  • Shanghai, China
    Shanghai Chest Hospital, Shanghai Jiao Tong University
Aug 21, 2023

Esophageal Cancer Trial in Tianjin (Arm A, Arm B)

Not yet recruiting
  • Esophageal Cancer
  • Arm A
  • Arm B
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Sep 24, 2023

Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (LBL-007,

Not yet recruiting
  • Esophageal Cancer
  • +2 more
  • (no location specified)
Aug 21, 2023

Locally Advanced Esophageal Squamous Cell Carcinoma Trial in Taipei (Nivolumab)

Recruiting
  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Taipei, Taiwan
    National Taiwan University Hospital
Nov 22, 2021

Toxicity, Drug Trial in Hefei (neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery)

Recruiting
  • Toxicity, Drug
  • neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
  • Hefei, Anhui, China
    Anhui Provicial Hospital
May 1, 2022

Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Cadonilimab combined Anlotinib
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023

Locally Advanced Esophageal Squamous Cell Carcinoma Trial in Tokyo (Nivolumab, 5-FU, CDDP)

Recruiting
  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Nivolumab
  • +3 more
  • Tokyo, Japan
    National Cancer Center Hospital
Apr 5, 2022